These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36799961)

  • 21. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.
    Li WC; Chen LF; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Affect Disord; 2023 Aug; 335():105-110. PubMed ID: 37178823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.
    Aepfelbacher J; Panny B; Price RB
    Biol Psychiatry Glob Open Sci; 2024 Jul; 4(4):100316. PubMed ID: 38726038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
    Echegaray MVF; Mello RP; Magnavita GM; Leal GC; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Bandeira ID; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Marback RF; Souza-Marques B; Lins-Silva DH; Santos-Lima C; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
    Trends Psychiatry Psychother; 2023 Sep; ():. PubMed ID: 37717263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
    Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
    Mello RP; Echegaray MVF; Jesus-Nunes AP; Leal GC; Magnavita GM; Vieira F; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Souza-Marques B; Bandeira ID; Santos-Lima C; Marback RF; Correia-Melo FS; Lacerda ALT; Quarantini LC
    J Psychiatr Res; 2021 Jun; 138():576-583. PubMed ID: 33991996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
    Jelovac A; McCaffrey C; Terao M; Shanahan E; Mohamed E; Whooley E; McDonagh K; McDonogh S; Igoe A; Loughran O; Shackleton E; O'Neill C; McLoughlin DM
    BMC Psychiatry; 2023 Nov; 23(1):850. PubMed ID: 37974160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
    Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
    Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
    Grunebaum MF; Galfalvy HC; Choo TH; Keilp JG; Moitra VK; Parris MS; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ
    Am J Psychiatry; 2018 Apr; 175(4):327-335. PubMed ID: 29202655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
    van Schalkwyk GI; Wilkinson ST; Davidson L; Silverman WK; Sanacora G
    J Affect Disord; 2018 Feb; 227():11-16. PubMed ID: 29045915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
    Cullen KR; Amatya P; Roback MG; Albott CS; Westlund Schreiner M; Ren Y; Eberly LE; Carstedt P; Samikoglu A; Gunlicks-Stoessel M; Reigstad K; Horek N; Tye S; Lim KO; Klimes-Dougan B
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):437-444. PubMed ID: 30004254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
    Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
    Mathai DS; Meyer MJ; Storch EA; Kosten TR
    J Affect Disord; 2020 Mar; 264():123-129. PubMed ID: 32056741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.